Evangelos Giampazolias, PhD
Group Leader
Cancer Research UK Manchester Institute
Manchester, UKEvangelos Giampazolias received his BSc in Chemistry (2009) and MSc in Clinical Biochemistry (2012) from the University of Athens in Greece. During his PhD (2012- 2016) at the CRUK Beatson Institute (Glasgow, UK), he discovered the pro inflammatory signals that accompany caspase-independent cell death and their impact on cancer immunity. For this, he was awarded the Institute of Cancer Sciences Prize (2017) and the CRUK Pontecorvo Prize (2018). Evangelos subsequently joined the group of Professor Caetano Reis e Sousa at the Francis Crick Institute (London, UK) as a Postdoctoral Fellow. There, he identified that the plasma actin-scavenging system dampens cancer immunity by hijacking immune mechanisms of dead cell sensing in the tumour microenvironment. He was granted an innovation patent (2020) to explore the therapeutic potential of these findings as novel immunotherapies. Further to this, Evangelos studied the influence of host-microbiome interactions in cancer immunity. He identified hosts factors that dictate the ability of gut microbiota to promote systemic anti-tumour immune responses. In 2023, Evangelos established his group at the CRUK Manchester Institute, which focuses on the characterisation of the mechanisms that enable the immune system to respond to cancer through integration of cues that are elicited by dying cells and commensal microbes.
︎ Visit the speaker’s lab here
︎ Learn more about the speaker here
